Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 12;47(4):947–957. doi: 10.1007/s00259-019-04530-1

Fig. 6.

Fig. 6

A 45-year-old man with pancreatic neuroendocrine tumor (G2, primary tumor removal), was accompanied with diarrhea, flushing and hyperglycemia. (A-C) Baseline 68Ga-DOTATATE PET/CT before administration with 4.14 GBq 177Lu-DOTA-EB-TATE. (D-F) 2 months post-therapy 68Ga-DOTATATE PET/CT showed volume reduction and decreased uptake of metastatic liver lesions(arrows) from 54.4 to 26.5.